de Paula B - Search Results

1

Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial.

Crocamo S, Binato R, de Paula B, Vignal G, Magalhães L, Sarmento R, Accioly MT, Small I, Gioia S, Maroun P, Moutinho P, Freitas V, Catein K, Abdelhay E. Crocamo S, et al. Among authors: de paula b. Ther Adv Med Oncol. 2019 May 31;11:1758835919853971. doi: 10.1177/1758835919853971. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31210800 Free PMC article.

2

Sociodemographic, Clinical, and Pathological Factors Influencing Outcomes in Locally Advanced Triple Negative Breast Cancer: A Brazilian Cohort.

da Silva JL, de Paula BHR, Small IA, Thuler LCS, de Melo AC. da Silva JL, et al. Breast Cancer (Auckl). 2020 Sep 25;14:1178223420962488. doi: 10.1177/1178223420962488. eCollection 2020. Breast Cancer (Auckl). 2020. PMID: 33029072 Free PMC article.

3

Real-world assessment of the effect of impact of tumor size on pathological complete response rates in triple negative breast cancer after neoadjuvant chemotherapy.

de Paula BHR, Kumar S, Morosini FM, Calábria Cardoso DEM, de Sousa CAM, Crocamo S. de Paula BHR, et al. Chin Clin Oncol. 2020 Dec;9(6):78. doi: 10.21037/cco-20-111. Epub 2020 Nov 10. Chin Clin Oncol. 2020. PMID: 33183012 Free article.

4

Is it time to retire sentinel lymph node biopsy and use multi-omics prediction models?

Kieran R, Goksu M, Crocamo S, de Paula B. Kieran R, et al. Among authors: de paula b. Ann Transl Med. 2022 Jun;10(12):655. doi: 10.21037/atm-2022-21. Ann Transl Med. 2022. PMID: 35845486 Free PMC article. No abstract available.

5

Considerations of systemic treatment for matrix-producing carcinoma with curative intent.

de Paula B, Palma Dos Reis AF, Crocamo S. de Paula B, et al. Gland Surg. 2022 Sep;11(9):1447-1450. doi: 10.21037/gs-22-490. Gland Surg. 2022. PMID: 36221274 Free PMC article. No abstract available.

6

Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer.

Crocamo S, Binato R, Dos Santos EC, de Paula B, Abdelhay E. Crocamo S, et al. Among authors: de paula b. Int J Mol Sci. 2022 Dec 8;23(24):15515. doi: 10.3390/ijms232415515. Int J Mol Sci. 2022. PMID: 36555156 Free PMC article. Clinical Trial.

7

Targeting Senescence as a Therapeutic Opportunity for Triple-Negative Breast Cancer.

de Paula B, Kieran R, Koh SSY, Crocamo S, Abdelhay E, Muñoz-Espín D. de Paula B, et al. Mol Cancer Ther. 2023 May 4;22(5):583-598. doi: 10.1158/1535-7163.MCT-22-0643. Mol Cancer Ther. 2023. PMID: 36752780 Free PMC article. Review.

8

Survival outcomes of Zo-NAnTAx: a five-year analysis of zoledronic acid added to a neoadjuvant regimen for HER2-positive breast cancer.

de Paula B, Abdelhay E, de Sousa CAM, Crocamo S. de Paula B, et al. Ann Transl Med. 2024 Jun 10;12(3):48. doi: 10.21037/atm-23-1880. Epub 2024 Apr 3. Ann Transl Med. 2024. PMID: 38911562 Free PMC article.

9

Nuclear and Cytoplasmic hTERT, Tumor-Infiltrating Lymphocytes, and Telomere Elongation Leukocytes Are Independent Factors in the Response to Neoadjuvant Treatment in HER2-Enriched Breast Cancer.

Delmonico L, Bines J, Nascimento CMD, Fernandes PV, Barbosa IS, Ribeiro GB, de Paula BHR, Silvestre RT, Ornellas MHF, Alves G, Lage C. Delmonico L, et al. Curr Oncol. 2023 Apr 7;30(4):4094-4109. doi: 10.3390/curroncol30040311. Curr Oncol. 2023. PMID: 37185424 Free PMC article.

10

A closer look at chemotherapy-induced flagellate dermatitis.

Constantinou A, Kotecha D, Laouris P, de Paula B. Constantinou A, et al. Among authors: de paula b. Skin Health Dis. 2022 Jan 19;2(1):e92. doi: 10.1002/ski2.92. eCollection 2022 Mar. Skin Health Dis. 2022. PMID: 35665202 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86 results

Search Page

Filters